Comparison of Secretin-enhanced Magnetic Resonance Cholangiopancreatography (S-MRCP) to Endoscopic Pancreatic Function Test (ePFT) in Diagnosing Pancreatic Exocrine Insufficiency

• Status: Withdrawn
• Trial end date: 2012-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of our study is to evaluate S-MRCP, in comparison to direct pancreatic function, to measure pancreatic exocrine function in patients who have symptoms suspicious for insufficiency. We hypothesize that S-MRCP imaging parameters will correlate well with the direct pancreatic exocrine functioning.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Columbia University
• Treatments: Secretin

Criteria

Inclusion Criteria:

• 18 years of age and older

• Tissue-confirmed diagnosis of pancreatic adenocarcinoma

• Undergone surgical resection for adenocarcinoma no less than 3 months prior to enrollment

• Report significant abdominal pain/bloating or steatorrhea >3x/week or demonstrate weight loss corresponding to >10% of pre-surgery BMI.

• Scheduled for EGD/EUS to investigate the above clinical indicators.

Exclusion Criteria:

• History of any radiation therapy to the abdomen prior to surgery

• Any contraindication to MRI, including but not limited to implanted metal devices (e.g. pacemaker, berry aneurysm clips, neural stimulator, cochlear implants, or metal in the eye)

• Presence of pancreatic duct stent

• Treatment with an investigational drug within 1 month prior to the day of the study drug administration

• Current enrollment in any other interventional study

• Creatinine greater than 2.0

• Significant liver disease, liver masses, or evidence of portal hypertension

• Pregnancy

• History of sensitivity to secretin

• Unwilling or unable to sign informed consent